Literature DB >> 21985516

Low prevalence of invasive bacterial infection in febrile infants under 3 months of age with enterovirus infection.

A Martínez Planas1, C Muñoz Almagro, C Luaces Cubells, A Noguera Julián, L Selva, J Pou Fernández, J J García García.   

Abstract

Infants under 3 months of age with fever without source (FWS) generally undergo a full, invasive septic evaluation to exclude invasive bacterial infection (IBI). Enterovirus (EV) infections are mostly banal and self-limiting and show a high prevalence rate at this age. We aimed to investigate the prevalence of IBI in EV-infected and uninfected infants under 3 months of age with FWS. This was a prospective observational cohort study of infants aged <90 days who were admitted because of FWS. As per protocol, blood and urine analysis and culture were obtained in all cases, and RNA EV from blood and/or cerebrospinal fluid samples was determined by real-time PCR. Three hundred and eighty-one previously healthy infants with FWS were included. EV infection was diagnosed in 64 children (16.8%; 95% confidence interval, 13.2-20.9%) and showed an uneventful evolution in all cases. Laboratory markers of infection were consistently lower in EV-infected patients; only one case of IBI (1.6%) was observed in an EV-infected patient as compared with 25.2% in EV-negative infants (p <0.001). Intravenous antibiotic use and length of stay were no different in EV-infected and uninfected patients. In our study, febrile infants (<90 days) diagnosed with EV infection showed a low risk of IBI when compared with uninfected patients. The systematic investigation of EV infection in young infants with FWS may allow a more conservative approach to the management of these patients. Further studies on this diagnostic approach are needed.
© 2011 The Authors. Clinical Microbiology and Infection © 2011 European Society of Clinical Microbiology and Infectious Diseases.

Entities:  

Mesh:

Year:  2011        PMID: 21985516     DOI: 10.1111/j.1469-0691.2011.03671.x

Source DB:  PubMed          Journal:  Clin Microbiol Infect        ISSN: 1198-743X            Impact factor:   8.067


  6 in total

1.  Clinical characteristics and molecular epidemiology of Enterovirus infection in infants <3 months in a referral paediatric hospital of Barcelona.

Authors:  Diana Rodà; Esther Pérez-Martínez; María Cabrerizo; Gloria Trallero; Aina Martínez-Planas; Carles Luaces; Juan-José García-García; Carmen Muñoz-Almagro; Cristian Launes
Journal:  Eur J Pediatr       Date:  2015-05-24       Impact factor: 3.183

2.  Outcomes and infectious etiologies of febrile neutropenia in non-immunocompromised children who present in an emergency department.

Authors:  C Pascual; V Trenchs; S Hernández-Bou; A Català; A F Valls; C Luaces
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2016-06-18       Impact factor: 3.267

3.  Role of Viral Molecular Panels in Diagnosing the Etiology of Fever in Infants Younger Than 3 Months.

Authors:  Cristina Epalza; Marie Hallin; Laurent Busson; Sara Debulpaep; Paulette De Backer; Olivier Vandenberg; Jack Levy
Journal:  Clin Pediatr (Phila)       Date:  2019-11-09       Impact factor: 1.168

4.  Clinical utility of procalcitonin in febrile infants younger than 3 months of age visiting a pediatric emergency room: a retrospective single-center study.

Authors:  Jun-Sung Park; Young-Hoon Byun; Jeong-Yong Lee; Jong Seung Lee; Jeong-Min Ryu; Seung Jun Choi
Journal:  BMC Pediatr       Date:  2021-03-04       Impact factor: 2.125

5.  Antibiotic Use in Febrile Children Presenting to the Emergency Department: A Systematic Review.

Authors:  Elles M F van de Voort; Santiago Mintegi; Alain Gervaix; Henriette A Moll; Rianne Oostenbrink
Journal:  Front Pediatr       Date:  2018-10-08       Impact factor: 3.418

6.  Impact of rapid enterovirus polymerase chain reaction testing on management of febrile young infants < 90 days of age with aseptic meningitis.

Authors:  Paolo Paioni; Florence Barbey; Christa Relly; Patrick Meyer Sauteur; Christoph Berger
Journal:  BMC Pediatr       Date:  2020-04-16       Impact factor: 2.125

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.